
Andrew P. Lee
Examiner (ID: 2259, Phone: (571)270-1016 , Office: P/1621 )
| Most Active Art Unit | 1621 |
| Art Unit(s) | 1691, 1628, 1621, 1629 |
| Total Applications | 711 |
| Issued Applications | 291 |
| Pending Applications | 92 |
| Abandoned Applications | 334 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19297512
[patent_doc_number] => 20240226077
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-11
[patent_title] => Compositions and Methods for Increasing Athletic Performance
[patent_app_type] => utility
[patent_app_number] => 18/609892
[patent_app_country] => US
[patent_app_date] => 2024-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10231
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18609892
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/609892 | Compositions and methods for increasing athletic performance | Mar 18, 2024 | Issued |
Array
(
[id] => 19510506
[patent_doc_number] => 20240342192
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => METHODS OF TREATING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 18/607971
[patent_app_country] => US
[patent_app_date] => 2024-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18607971
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/607971 | METHODS OF TREATING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) DYSFUNCTION | Mar 17, 2024 | Pending |
Array
(
[id] => 20505041
[patent_doc_number] => 12539303
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-03
[patent_title] => RET inhibitor for use in treating cancer having a RET alteration
[patent_app_type] => utility
[patent_app_number] => 18/606346
[patent_app_country] => US
[patent_app_date] => 2024-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 26
[patent_no_of_words] => 5597
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606346
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/606346 | RET inhibitor for use in treating cancer having a RET alteration | Mar 14, 2024 | Issued |
Array
(
[id] => 20328368
[patent_doc_number] => 12458625
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-04
[patent_title] => Methods and compositions for soft anticholinergic esters
[patent_app_type] => utility
[patent_app_number] => 18/600632
[patent_app_country] => US
[patent_app_date] => 2024-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7835
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18600632
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/600632 | Methods and compositions for soft anticholinergic esters | Mar 7, 2024 | Issued |
Array
(
[id] => 19909207
[patent_doc_number] => 12285391
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-04-29
[patent_title] => System and method for non-surgical treatment of prolapsed hemorrhoids
[patent_app_type] => utility
[patent_app_number] => 18/429785
[patent_app_country] => US
[patent_app_date] => 2024-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 0
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429785
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/429785 | System and method for non-surgical treatment of prolapsed hemorrhoids | Jan 31, 2024 | Issued |
Array
(
[id] => 20264056
[patent_doc_number] => 12435031
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-07
[patent_title] => Compound with broad-spectrum antibacterial activity and its antibacterial composition
[patent_app_type] => utility
[patent_app_number] => 18/843258
[patent_app_country] => US
[patent_app_date] => 2024-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 1659
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18843258
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/843258 | Compound with broad-spectrum antibacterial activity and its antibacterial composition | Jan 25, 2024 | Issued |
Array
(
[id] => 19479329
[patent_doc_number] => 20240327371
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/418122
[patent_app_country] => US
[patent_app_date] => 2024-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 271126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18418122
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/418122 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | Jan 18, 2024 | Issued |
Array
(
[id] => 19584888
[patent_doc_number] => 20240382445
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => METHODS OF ADJUVANT THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/408485
[patent_app_country] => US
[patent_app_date] => 2024-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18408485
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/408485 | METHODS OF ADJUVANT THERAPY | Jan 8, 2024 | Abandoned |
Array
(
[id] => 19216166
[patent_doc_number] => 20240180870
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 18/406732
[patent_app_country] => US
[patent_app_date] => 2024-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33874
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18406732
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/406732 | Methods of treating conditions related to the S1P | Jan 7, 2024 | Issued |
Array
(
[id] => 19279871
[patent_doc_number] => 20240216343
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => ENDOTHELIAL IK AND SK CHANNEL ACTIVATION TO TREAT PULMONARY HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 18/403572
[patent_app_country] => US
[patent_app_date] => 2024-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13397
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18403572
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/403572 | ENDOTHELIAL IK AND SK CHANNEL ACTIVATION TO TREAT PULMONARY HYPERTENSION | Jan 2, 2024 | Pending |
Array
(
[id] => 19111169
[patent_doc_number] => 20240122919
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/394435
[patent_app_country] => US
[patent_app_date] => 2023-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8675
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18394435
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/394435 | KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE | Dec 21, 2023 | Pending |
Array
(
[id] => 19111156
[patent_doc_number] => 20240122906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => METHODS OF TREATING MELANOMA WITH RIPRETINIB
[patent_app_type] => utility
[patent_app_number] => 18/505396
[patent_app_country] => US
[patent_app_date] => 2023-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12265
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18505396
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/505396 | METHODS OF TREATING MELANOMA WITH RIPRETINIB | Nov 8, 2023 | Pending |
Array
(
[id] => 19263510
[patent_doc_number] => 20240207207
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES
[patent_app_type] => utility
[patent_app_number] => 18/388023
[patent_app_country] => US
[patent_app_date] => 2023-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21496
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18388023
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | Nov 7, 2023 | Pending |
Array
(
[id] => 19550926
[patent_doc_number] => 12134622
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-11-05
[patent_title] => 2-benzo-[3,4-b]pyridine-[b,g]indeno[1,2;3,4]fluoreno-[1,2-d]oxonine-5,11,16,21-tetraone as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/387345
[patent_app_country] => US
[patent_app_date] => 2023-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3845
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18387345
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/387345 | 2-benzo-[3,4-b]pyridine-[b,g]indeno[1,2;3,4]fluoreno-[1,2-d]oxonine-5,11,16,21-tetraone as an antimicrobial compound | Nov 5, 2023 | Issued |
Array
(
[id] => 19651204
[patent_doc_number] => 12172972
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-12-24
[patent_title] => 3-(3-bromophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/386347
[patent_app_country] => US
[patent_app_date] => 2023-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4472
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386347
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/386347 | 3-(3-bromophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound | Nov 1, 2023 | Issued |
Array
(
[id] => 19909247
[patent_doc_number] => 12285432
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-29
[patent_title] => Treatment of hair loss disorders with deuterated JAK inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/382307
[patent_app_country] => US
[patent_app_date] => 2023-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10427
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382307
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/382307 | Treatment of hair loss disorders with deuterated JAK inhibitors | Oct 19, 2023 | Issued |
Array
(
[id] => 19921684
[patent_doc_number] => 12295943
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Apixaban dosing
[patent_app_type] => utility
[patent_app_number] => 18/472660
[patent_app_country] => US
[patent_app_date] => 2023-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 22
[patent_no_of_words] => 21118
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 153
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472660
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/472660 | Apixaban dosing | Sep 21, 2023 | Issued |
Array
(
[id] => 18937428
[patent_doc_number] => 20240032567
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => IMPROVED ANIMAL FEED COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/466041
[patent_app_country] => US
[patent_app_date] => 2023-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32718
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18466041
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/466041 | IMPROVED ANIMAL FEED COMPOSITIONS AND METHODS OF USE | Sep 12, 2023 | Pending |
Array
(
[id] => 18860107
[patent_doc_number] => 20230414541
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => METHODS OF TREATING NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION
[patent_app_type] => utility
[patent_app_number] => 18/462238
[patent_app_country] => US
[patent_app_date] => 2023-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18462238
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/462238 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION | Sep 5, 2023 | Pending |
Array
(
[id] => 18901314
[patent_doc_number] => 20240016799
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/355811
[patent_app_country] => US
[patent_app_date] => 2023-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37979
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18355811
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/355811 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | Jul 19, 2023 | Issued |